Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe-Reference-Cited by-同舟云学术

Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe

Published:2020-01-16 Issue:1 Volume:15 Page:e0227914
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Armuzzi Alessandro,DiBonaventura Marco daCosta,Tarallo Miriam,Lucas James,Bluff Daniel,Hoskin Benjamin,Bargo Danielle,Cappelleri Joseph C.,Quirk Daniel,Salese Leonardo

Funder

Pfizer Inc

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference17 articles.

1. Epidemiology and natural history of inflammatory bowel diseases;J Cosnes;Gastroenterology,2011

2. Ulcerative colitis;R Ungaro;Lancet,2017

3. Survey of digestive health across Europe: Final report. Part 1: The burden of gastrointestinal diseases and the organisation and delivery of gastroenterology services across Europe;M Farthing;United European Gastroenterol J,2014

4. The burden of inflammatory bowel disease in Europe;J Burisch;J Crohns Colitis,2013

5. The facts about inflammatory bowel disease;Crohn's & Colitis Foundation of America,2014

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Treatment Persistence Among Advanced Therapy-Naïve or -Experienced Patients with Ulcerative Colitis Initiated on Ustekinumab or Adalimumab;Advances in Therapy;2024-08-14

2. Outcome of Biological Therapies and Small Molecules in Ulcerative Proctitis: A Belgian Multicenter Cohort Study;Clinical Gastroenterology and Hepatology;2024-01

3. Causal relationship between asthma and ulcerative colitis and the mediating role of interleukin-18: a bidirectional Mendelian study and mediation analysis;Frontiers in Immunology;2023-12-14

4. Biologics and the timing of operative management of pediatric inflammatory bowel disease;Journal of Pediatric Surgery Open;2023-12

5. A randomized, double‐blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate to severe active ulcerative colitis;Clinical and Translational Medicine;2023-11